Pimozide 2mg/day (current) or 4 mg/day (study initiation) ( DrugBank: Pimozide )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03272503 (ClinicalTrials.gov) | October 27, 2017 | 31/8/2017 | A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase II Randomized, Placebo-Controlled, Double Blinded, Multi-Centre Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis | ALS;Amyotrophic Lateral Sclerosis | Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation);Drug: Placebo Oral Tablet | University of Calgary | ALS Canada;Brain Canada | Recruiting | 18 Years | N/A | All | 100 | Phase 2 | Canada |